ANVISA determines the withdrawal of losartan-based medications used for high blood pressure.

ANVISA (National Health Surveillance Agency) this Thursday (23) determined the ban on the batches of drugs and the return of drugs containing the active ingredient Lucartan, an antihypertensive and the most widely used heart failure in Brazil. Is one of the medicines. According to the agency, the decision was made due to the presence of azide impurities in acceptable concentrations.

The maximum regulatory deadline for collecting products from pharmacies is 120 days, counting from today, the date of publication of the resolution, for which Anvisa reviewed the impact on the Brazilian market and the need for continuity of treatment.

Click here To consult a list of upcoming batches Plural.

Click here To consult a list of lots that have been banned.

The Anvisa Pharmaceutical Market Statistical Yearbook shows that Losartan Potassium, in 2019, was the second most commercially active ingredient in the country, second only to sodium chloride, used as a decongestant, for various injectable drugs or wounds. As a vehicle for cleaning, among other things. .

Anvisa warns that people who use the drug should not interfere with their treatment. He added that high blood pressure and heart disease require constant monitoring and that any change in treatment should be made only by the doctor accompanying the patient. Failure to take the medication can increase the risk of stroke and heart attack among others.

Anvisa explained that the precautionary measure was adopted after the evolution of knowledge about impurities, and that it works to adapt the products used in Brazil to the technical limitations that are presented for the presence of the contamination under discussion. Were gone

Many were affected by the use.

For those who are using infected batches of medicine, Anvisa ‘s advice is to continue treatment and talk to a doctor if you have any questions or need guidance.

The explanation for this decision is that there is no immediate risk to the use of this drug, as there are no data indicating an increase in adverse events.

The agency says there are other losartans on the market that can replace withdrawn or discontinued drugs, but should only be exchanged under a prescription and when the user already has a new drug.

Patients can also contact the SAC (Customer Service) of the manufacturing laboratory to inquire about the exchange of medicines for this batch that has not been affected by recall or suspension.

Means of contacting companies are available on packaging and product booklets.

In a note, Anvisa explained that, since the discovery of the possibility of azide in Lassarten in September 2021, she has been taking steps to ensure that the medicines available to the Brazilian population meet the standard. Be inside

Anvisa informed the registration holders of these drugs that it was necessary to present the results of the assessment regarding the presence of this contamination in their products.

Lasartan is considered a safe and effective drug, so registration of these drugs is valid in Brazil and many other countries.


Leave a Comment

Your email address will not be published.